Loading clinical trials...
Loading clinical trials...
A Phase 2a Study to Compare Antiviral Effect, Safety, Tolerability and Pharmacokinetics of GSK1265744 Monotherapy Versus Placebo in HIV-1 Infected Adults (ITZ112929)
Conditions
Interventions
GSK1265744 30mg
Placebo
+1 more
Locations
4
United States
GSK Investigational Site
Fort Lauderdale, Florida, United States
GSK Investigational Site
Orlando, Florida, United States
GSK Investigational Site
Vero Beach, Florida, United States
GSK Investigational Site
Charlotte, North Carolina, United States
Start Date
June 9, 2009
Primary Completion Date
August 13, 2009
Completion Date
August 13, 2009
Last Updated
December 6, 2017
NCT06719310
NCT02831673
NCT02075593
NCT01231516
NCT02178592
NCT02415595
Lead Sponsor
ViiV Healthcare
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions